{"name":"Adlai Nortye Biopharma Co., Ltd.","slug":"adlai-nortye-biopharma-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"AN0025","genericName":"AN0025","slug":"an0025","indication":"Other","status":"phase_1"},{"name":"AN2025","genericName":"AN2025","slug":"an2025","indication":"Other","status":"phase_1"},{"name":"AN4005-dose level 0","genericName":"AN4005-dose level 0","slug":"an4005-dose-level-0","indication":"Other","status":"phase_1"},{"name":"AN4005-dose level 1","genericName":"AN4005-dose level 1","slug":"an4005-dose-level-1","indication":"Other","status":"phase_1"},{"name":"AN4005-dose level 2","genericName":"AN4005-dose level 2","slug":"an4005-dose-level-2","indication":"Other","status":"phase_1"},{"name":"AN4005-dose level 3","genericName":"AN4005-dose level 3","slug":"an4005-dose-level-3","indication":"Other","status":"phase_1"},{"name":"AN4005-dose level 4","genericName":"AN4005-dose level 4","slug":"an4005-dose-level-4","indication":"Other","status":"phase_1"},{"name":"AN4005-food effect","genericName":"AN4005-food effect","slug":"an4005-food-effect","indication":"Other","status":"phase_1"},{"name":"AN9025 oral capsule","genericName":"AN9025 oral capsule","slug":"an9025-oral-capsule","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Buparlisib & Paclitaxel","genericName":"Buparlisib & Paclitaxel","slug":"buparlisib-paclitaxel","indication":"Metastatic breast cancer (phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"AN0025","genericName":"AN0025","slug":"an0025","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AN2025","genericName":"AN2025","slug":"an2025","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AN4005-dose level 0","genericName":"AN4005-dose level 0","slug":"an4005-dose-level-0","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AN4005-dose level 1","genericName":"AN4005-dose level 1","slug":"an4005-dose-level-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AN4005-dose level 2","genericName":"AN4005-dose level 2","slug":"an4005-dose-level-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AN4005-dose level 3","genericName":"AN4005-dose level 3","slug":"an4005-dose-level-3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AN4005-dose level 4","genericName":"AN4005-dose level 4","slug":"an4005-dose-level-4","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AN4005-food effect","genericName":"AN4005-food effect","slug":"an4005-food-effect","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AN9025 oral capsule","genericName":"AN9025 oral capsule","slug":"an9025-oral-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Buparlisib & Paclitaxel","genericName":"Buparlisib & Paclitaxel","slug":"buparlisib-paclitaxel","phase":"phase_3","mechanism":"Buparlisib inhibits PI3K signaling while paclitaxel stabilizes microtubules to prevent cell division, together targeting cancer cell proliferation through complementary pathways.","indications":["Metastatic breast cancer (phase 3 development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPd3VKVnNfeXRBdHVmLTdkak1PQThGSWpGU2t2WXRCQ1ppSDdEN1UzZEthbUFQMEFmV3ZqdHRGcVNJVUM1Z0M4LW92ckxQRmlDcWxXNG9NOVRhUFBjdnRtTV8wY1BydGw1YWUtT2k3aGhBT0JTQ3F0eVowS1h6N0tzVmtWS3NRbnljZHhISjE2R2dBU09OV0d3OFBNdU9yOFViNENaMWVVT0cxc0NYZTNZOQ?oc=5","date":"2026-04-01","type":"pipeline","source":"Stock Titan","summary":"Leadership reshuffle at Adlai Nortye (ANL) as new president and CFO - Stock Titan","headline":"Leadership reshuffle at Adlai Nortye (ANL) as new president and CFO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOaXIwdXo3TmdMV0lDWWFqRGQxN1pzaHNheUJQRE1oeWVLWVFKX3pValZabEV6OWMzQUQ3ZGh5MEppeXdnUmNXUUJ1VDBoVFJuUDBwYjdGci1qRDQtSmxaejZGSS10RS1CTWtVVkdFYnNLc0N5RXpjbHhEZUo5ZXBfeXlfcGdKNlNob0FsLTYyN2N3eE9sWG1MRENVRG5RU2txTjc2ZjdJUC0yTUI4bWtlZ0JnN09fX0hnVnhGNlpvS2VtM2E4TEcybmtwSQ?oc=5","date":"2026-04-01","type":"pipeline","source":"TipRanks","summary":"Adlai Nortye Reshapes Top Leadership as President Retires and R&D Chief Steps Up - TipRanks","headline":"Adlai Nortye Reshapes Top Leadership as President Retires and R&D Chief Steps Up","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-28","type":"pipeline","source":"simplywall.st","summary":"Adlai Nortye Ltd.'s (NASDAQ:ANL) market cap surged US$65m last week, retail investors who have a lot riding on the company were rewarded - simplywall.st","headline":"Adlai Nortye Ltd.'s (NASDAQ:ANL) market cap surged US$65m last week, retail investors who have a lot riding on the compa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxNRGNJOEMxbXhpMUJEc0lsLTZCNTB0YzY1aUd2eDAwcy1HbFJoREZ0dnYyVzhHcG5QR2tPLUk4WGFxNlVBbV9OOXc0dHJycHN3bUVMLTBxb3Zwb0pLc2dObEtxSzh4LTZpSHFYcU1uN1RyM3Z6MUZHU1VxWDVYNTA2clh2Qng2elR2Xy1MYXoxSUxCUTNlaDVvVlg2TjJsZC1tcTQ0MHprd2dBY0J2Vi1yeHFzZnFoQkNsbkwwaHZaaThFQW9iLUpBRlZ5TUtZS1lBRkF3U1BOQ0tIRGdrSC0yd1lnWFhSY2NjY1U3OHJZRzNpMU1Bd1JiU3FaRlhUM1REVFh4eWhIRzZkcjcyUVk5dA?oc=5","date":"2025-12-29","type":"deal","source":"GlobeNewswire","summary":"Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - GlobeNewswire","headline":"Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQOVh0R2FLakJvazEtcGdrbU5VS09sT3d4b21pTjlLcjM0R0FFamkwRHowTFVXdTJ4RWRrOVJwRTM4ald2dFdHUXdPa182VVBFVXFiY2c4VUdGclY1VjIxYnlkUDNVQXhrVTJJWFVDMmJ2QklhMDNodWxCYXljVnJCNkZUcG5makF6amhYX0xma3RSVG0yaVE?oc=5","date":"2023-09-29","type":"pipeline","source":"BioPharma Dive","summary":"Adlai Nortye IPO gives old Novartis cancer drug new life - BioPharma Dive","headline":"Adlai Nortye IPO gives old Novartis cancer drug new life","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNd2xUa0NQWmJXelc2YXB5SmRpUWxKbXRVNWZlODE3RkJhOHNVZVlqazN5R0Q3bUxhUDhtWTdsY2NjNkVvdUt0RzZheDJWLXBhRXlGR2xqNGtwb3ZZUDNFeUpHeGtyRy1mcWVtclJiN0NtOFNDZU1uVV9acldfMVVaeVExTV9NVEdvLVBWVUZ3M2hleUZE?oc=5","date":"2023-08-11","type":"pipeline","source":"Seeking Alpha","summary":"IPO Update: Adlai Nortye Readies $72 Million U.S. IPO (Pending:ANL) - Seeking Alpha","headline":"IPO Update: Adlai Nortye Readies $72 Million U.S. IPO (Pending:ANL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQa1RxdU85WGh4dG5FQmNBZENkck5XQWFDWXIyaTJwa0RZRV9JN3phNk9aazU0WFhRNTh3UHpLQUFMOV9leEo5SUx4b1RvSVNPcGJSWGxoc3dJNElQM3F2MHVuR0RuNkVKOFU3eTNNdWQ5WHBPdUVNLWJjUzU4TWZUSGxTak05bUVVUF9YbjlnWlk3X2MtcEI2OGI5S090Y0w3clJKSDhvZlQ?oc=5","date":"2023-07-28","type":"pipeline","source":"BioWorld News","summary":"Aggressive licensor, cancer-focused Adlai Nortye files for US IPO - BioWorld News","headline":"Aggressive licensor, cancer-focused Adlai Nortye files for US IPO","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2018-08-23","type":"trial","source":"ET HealthWorld","summary":"Novartis trial win lifts profile of new breast cancer drug - ET HealthWorld","headline":"Novartis trial win lifts profile of new breast cancer drug","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"phase_1":9,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}